Solopharm's CEO, Mamuka Mikhelashvili, gave a major interview to RBC+ in which he outlined the key challenges and opportunities for the Russian pharmaceutical industry, and explained how the company is adapting to new conditions and formulating a strategy for sustainable growth.
According to Mamuka Mikhelashvili, the discussion on the development of Russian pharma today should be framed not in the context of import substitution, but of technological sovereignty.
He also noted that new regulations, including the «Second Redundant» principle, could pose a challenge for many Russian manufacturers:
«The 'Second Redundant' principle must be implemented smoothly and not by directive, because the beneficiary of directive-based regulation will be foreign pharma. A roadmap is needed that takes into account the realistic pace of the industry's technological development. Currently, the industry is not ready for the 'Second Redundant' principle», he emphasized.
One of the key topics of the interview was the issue of patent restrictions on imported drugs — especially in a situation where supplies could be abruptly discontinued by foreign companies.
The company's CEO paid special attention to biotechnological drugs — a sector poised to become the main driver of the pharmaceutical industry in the coming years. Solopharm is actively investing in its own biotech project and expects to launch its first drugs within the next few years.
Read the full interview at this link.
Photo source: RBC
